Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study.
Matsuda C, Honda M, Tanaka C, Kondo K, Takahashi T, Kosugi C, Tokunaga Y, Takemoto H, Kim HM, Sakamoto J, Oba K, Mishima H. Matsuda C, et al. Among authors: kim hm. Cancer Chemother Pharmacol. 2018 Jun;81(6):1035-1041. doi: 10.1007/s00280-018-3568-x. Epub 2018 Apr 11. Cancer Chemother Pharmacol. 2018. PMID: 29644459 Clinical Trial.
[Two cases of human epidermal growth factor receptor 2-positive advanced gastric cancer successfully treated with S-1, cisplatin, and trastuzumab combination therapy followed by curative resection].
Yasuyama A, Mikata S, Soma Y, Yoshikawa Y, Watase C, Kubota M, Miyake Y, Matsuura Y, Kim HM, Murakami M, Hirota M, Morishima H, Matsunami N, Hasegawa J, Miwa H, Nezu R. Yasuyama A, et al. Among authors: kim hm. Gan To Kagaku Ryoho. 2013 Nov;40(12):2203-6. Gan To Kagaku Ryoho. 2013. PMID: 24394060 Japanese.
Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.
Hasegawa J, Nishimura J, Mizushima T, Miyake Y, Kim HM, Takemoto H, Tamagawa H, Noura S, Fujii M, Fujie Y, Kato T, Miwa H, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Hasegawa J, et al. Among authors: kim hm. Cancer Chemother Pharmacol. 2014 May;73(5):1079-87. doi: 10.1007/s00280-014-2417-9. Epub 2014 Mar 5. Cancer Chemother Pharmacol. 2014. PMID: 24595805
First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer.
Uemura M, Kim HM, Hata T, Sakata K, Okuyama M, Takemoto H, Fujii H, Fukuzaki T, Morita T, Hata T, Takemasa I, Satoh T, Mizushima T, Doki Y, Mori M; Multi-Center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO). Uemura M, et al. Among authors: kim hm. Mol Clin Oncol. 2016 Aug;5(2):375-379. doi: 10.3892/mco.2016.938. Epub 2016 Jun 17. Mol Clin Oncol. 2016. PMID: 27446583 Free PMC article.
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea.
Takemoto H, Nishimura J, Komori T, Kim HM, Ota H, Suzuki R, Ikenaga M, Ikeda M, Yamamoto H, Satoh T, Hata T, Takemasa I, Mizushima T, Doki Y, Mori M; Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO). Takemoto H, et al. Among authors: kim hm. Int J Clin Oncol. 2017 Feb;22(1):88-95. doi: 10.1007/s10147-016-1022-9. Epub 2016 Jul 27. Int J Clin Oncol. 2017. PMID: 27465476 Clinical Trial.
3,326 results